Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 306.20 INR
Change Today 0.00 / 0.00%
Volume 0.0
As of 6:29 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

claris lifesciences ltd (CLAR) Snapshot

Open
312.90
Previous Close
310.30
Day High
312.90
Day Low
301.00
52 Week High
04/13/15 - 358.00
52 Week Low
06/2/14 - 141.25
Market Cap
16.7B
Average Volume 10 Days
432.2K
EPS TTM
24.95
Shares Outstanding
54.6M
EX-Date
01/20/14
P/E TM
12.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for CLARIS LIFESCIENCES LTD (CLAR)

Related News

No related news articles were found.

claris lifesciences ltd (CLAR) Related Businessweek News

No Related Businessweek News Found

claris lifesciences ltd (CLAR) Details

Claris Lifesciences Limited, together with its subsidiaries, operates as a sterile injectables pharmaceutical company worldwide. The company manufactures and markets products for anesthesia and analgesia; blood; anti-infectives, such as quinolone, beta lactum, anti-fungal, and aminoglycoside; and oncology segments. It also provides enteral nutrition products and delivery systems; and therapy, peritoneal dialysis products, and medicines for renal and transplant. In addition, the company offers injectables for various therapeutic groups, including anti-emetics, CNS, cardiology, anti-malaria, haematinics, etc in various delivery systems, such as glass bottles, vials, ampoules, and non-PVC/PVC bags. It serves government and private hospitals, aid agencies, and nursing homes. The company was incorporated in 1994 and is headquartered in Ahmedabad, India.

Founded in 1994

claris lifesciences ltd (CLAR) Top Compensated Officers

Vice Chairman, Managing Director and Member o...
Total Annual Compensation: 15.0M
Chief Financial Officer, Whole Time Director,...
Total Annual Compensation: 4.7M
Whole Time Director
Total Annual Compensation: 4.7M
Compensation as of Fiscal Year 2013.

claris lifesciences ltd (CLAR) Key Developments

Claris Lifesciences Limited Reports Audited Consolidated and Standalone Earnings Results for the Quarter and Fifteen Months Ended March 31, 2015

Claris Lifesciences Limited reported audited consolidated and standalone earnings results for the quarter and fifteen months ended March 31, 2015. For the quarter, on consolidated basis, net sales /income from operations was INR 1,547.280 million compared to INR 1,330.917 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 146.275 million compared to INR 88.243 million a year ago. Profit from ordinary activities before tax was INR 179.524 million against INR 191.976 million a year ago. Net profit was INR 125.015 million or INR 1.91 per basic and diluted share before and after extraordinary items compared to net profit of INR 154.126 million or INR 2.09 per basic and diluted share before and after extraordinary items a year ago. For the fifteen months, on consolidated basis, net sales /income from operations was INR 7,801.130 million compared to INR 6,583.755 million as of December 31, 2014. Profit from operations before other income finance cost and exceptional items was INR 1,064.250 million compared to INR 1,011.811 million as of December 31, 2014. Profit from ordinary activities before tax was INR 1,444.681 million against INR 1,074.855 million as of December 31, 2014. Net profit was INR 1,566.717 million or INR 25.89 per basic and diluted share before and after extraordinary items compared to net profit of INR 854.084 million or INR 13.23 per basic and diluted share before and after extraordinary items as of December 31, 2014. For the quarter, on standalone basis, net sales /income from operations was INR 1,307.543 million compared to INR 1,249.777 million a year ago. Loss from operations before other income finance cost and exceptional items was INR 142.022 million compared to profit INR 110.435 million a year ago. Profit from ordinary activities before tax was INR 42.307 million against INR 203.229 million a year ago. Net profit was INR 38.442 million or INR 0.70 per basic and diluted share before and after extraordinary items compared to net profit of INR 165.710 million or INR 2.60 per basic and diluted share before and after extraordinary items a year ago. For the six months, on standalone basis, net sales /income from operations was INR 7,022.216 million compared to INR 6,287.935 million as of December 31, 2014. Profit from operations before other income finance cost and exceptional items was INR 567.775 million compared to INR 969.031 million as of December 31, 2014. Profit from ordinary activities before tax was INR 1,072.190 million against INR 1,032.086 million as of December 31, 2014. Net profit was INR 1,386.896 million or INR 24.02 per basic and diluted share before and after extraordinary items compared to net profit of INR 812.185 million or INR 12.73 per basic and diluted share before and after extraordinary items as of December 31, 2014.

Cadila Healthcare Is Reported To Acquire Injectables Business Of Claris

Cadila Healthcare Limited (BSE:532321) has emerged as the front runner to acquire the generic sterile injectables business of Claris Lifesciences Limited (BSE:533288). Both Cadila and Claris are currently engaged in last-minute due diligence negotiations involving tax and other financial matters, said sources aware of the talks. Cadila is likely to pay a hefty premium, valuing the company at INR 31 billion to INR 34 billion. A formal announcement is expected early June 2015 provided there are no last-minute delays or glitches. The Cadila Healthcare spokesperson told Economic Times that as a matter of policy, the company does not comment on market speculation and a Claris spokesperson, however, denied any such development. Following the report, stock of Claris rallied as much as 17.79% in intraday trade on May 21, 2015.

Claris Lifesciences Limited, Board Meeting, May 22, 2015

Claris Lifesciences Limited, Board Meeting, May 22, 2015. Agenda: To consider audited results.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLAR:IN 306.20 INR 0.00

CLAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLAR.
View Industry Companies
 

Industry Analysis

CLAR

Industry Average

Valuation CLAR Industry Range
Price/Earnings 12.9x
Price/Sales 2.6x
Price/Book 1.3x
Price/Cash Flow 9.3x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLARIS LIFESCIENCES LTD, please visit www.clarislifesciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.